CREB3L2 Antibody

Western Blot: CREB3L2 Antibody [NBP1-88697]

Western Blot: CREB3L2 Antibody [NBP1-88697] - Expression of CREB3L2 in differentiating primary human B-cells. Protein expression of CREB3L2 during in vitro differentiation of primary human B-cells. The day of culture is indicated at the top. Intact and dashed arrows show migration of full-length protein and cleaved C-terminus, respectively. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/s41598-018-32705-7), licensed under a CC-BY license.

Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697]

Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human placenta shows strong nuclear and cytoplasmic positivity in trophoblastic cells.

Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697]

Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human kidney shows strong cytoplasmci positivity in cells in tubules.

Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697]

Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human fallopian tube shows moderate cytoplasmic positivity in glandular cells.

Western Blot: CREB3L2 Antibody [NBP1-88697] -

Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P inhibition induces autophagy & affects multiple UPR-related TFs. (A) In vitro day 3 B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) for 72 h & were assessed for cell number using CountBright beads. Shown are the average cell numbers from 7 donors ± standard deviations. Protein lysates generated from day 3 cells treated for 72 h with 10 μM PF-429242 were evaluated for (B) autophagy markers or (C) CREB3L2 & ATF6 by Western blotting. Shown are representative results from 2 donors, a total of 7 donors were evaluated. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CREB3L2 Antibody [NBP1-88697] -

Western Blot: CREB3L2 Antibody [NBP1-88697] - Kinetic & dose analysis of S1P-specific inhibitor PF-429242 during the early phase of ASC generation. (A) In vitro activated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 3 & assessed for CREB3L2 processing at 12 h intervals. Representative results are shown from a total of 7 donors. (B) Samples from part (A) were assessed for cell number at the indicated time points. Displayed are the average cell number ± standard deviation derived from 7 donors. (C) In vitro activated human B-cells from 4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 3 & assessed for cell number at 48 h. Results are displayed as the percentage viable cells relative to control. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CREB3L2 Antibody [NBP1-88697] -

Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P-specific inhibitor PF-429242 blocks CREB3L2 processing. (A) Diagram of CREB3L2 structure with proteolytic cleavage sites. Act domain, Activation Domain. bZIP, Basic Leucine Zipper Domain. TM, Transmembrane Domain. (B) In vitro generated human ASCs were treated with 10 μM PF-429242 or vehicle control (dH2O) on the day that appears first (d6, d8, d10) & protein lysates generated on the day that appears subsequently (d8, d10, d13) were analyzed by Western blotting. Intact & dashed arrows show migration of CREB3L2 full-length protein & cleaved C-terminus, respectively. (C) In vitro differentiated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 6 & analyzed subsequently for phenotype on the indicated days. Live cells were evaluated for expression of B-cell markers CD19 & CD20 & ASC markers CD38 & CD138. Percentages of cells are shown within the quadrant gates. The experiment was performed with 4 donors, a representative donor is shown. (D) Samples treated as in part (B) were assessed for cell number using CountBright beads. (E) In vitro activated human B-cells from 4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 6 & assessed for cell number at 48 h. Results are displayed as the percentage viable cells relative to control. Supernatants from samples in part (B) were analyzed by ELISA for production of (F) IgM & (G) IgG. Significance was determined by t-test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.